XTX Topco Ltd Has $351,000 Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

XTX Topco Ltd decreased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 70.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,919 shares of the company's stock after selling 21,103 shares during the period. XTX Topco Ltd's holdings in CRISPR Therapeutics were worth $351,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. ARK Investment Management LLC boosted its holdings in CRISPR Therapeutics by 19.7% in the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company's stock worth $353,180,000 after acquiring an additional 1,474,439 shares during the period. Norges Bank purchased a new stake in CRISPR Therapeutics during the 4th quarter worth $17,458,000. Contrarius Group Holdings Ltd acquired a new position in CRISPR Therapeutics in the 4th quarter worth $14,516,000. Raymond James Financial Inc. purchased a new position in CRISPR Therapeutics in the 4th quarter valued at about $3,231,000. Finally, Van ECK Associates Corp increased its position in shares of CRISPR Therapeutics by 5,269.3% during the fourth quarter. Van ECK Associates Corp now owns 83,010 shares of the company's stock worth $3,267,000 after acquiring an additional 81,464 shares during the last quarter. Institutional investors and hedge funds own 69.20% of the company's stock.

CRISPR Therapeutics Price Performance

Shares of NASDAQ CRSP traded up $0.17 during midday trading on Tuesday, hitting $38.05. 219,804 shares of the company's stock were exchanged, compared to its average volume of 2,160,662. CRISPR Therapeutics AG has a twelve month low of $30.04 and a twelve month high of $67.88. The firm has a market cap of $3.29 billion, a P/E ratio of -8.71 and a beta of 1.85. The stock's 50 day moving average price is $39.72 and its 200-day moving average price is $43.43.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. On average, analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Insiders Place Their Bets

In other CRISPR Therapeutics news, COO Julianne Bruno sold 1,198 shares of the company's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $50,819.16. Following the completion of the sale, the chief operating officer now directly owns 8,263 shares of the company's stock, valued at approximately $350,516.46. This represents a 12.66 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Samarth Kulkarni sold 18,360 shares of the stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the sale, the chief executive officer now owns 171,613 shares of the company's stock, valued at $9,473,037.60. The trade was a 9.66 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 32,381 shares of company stock worth $1,608,243. 4.10% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Citigroup lowered their price objective on CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating for the company in a research note on Tuesday, February 18th. Needham & Company LLC restated a "buy" rating and issued a $84.00 price target on shares of CRISPR Therapeutics in a research note on Wednesday, April 9th. The Goldman Sachs Group reduced their price objective on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a "neutral" rating on the stock in a research note on Thursday, February 13th. Stifel Nicolaus cut their target price on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating on the stock in a research note on Thursday, February 13th. Finally, JMP Securities reissued a "market outperform" rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, CRISPR Therapeutics has a consensus rating of "Hold" and an average target price of $73.11.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.